The small GTPase Rac1 regulates signaling pathways controlling actin-dependent cell motility as well as gene transcription. An alternative splicing variant Rac1b is overexpressed in a subset of colorectal tumors and is required to sustain tumor cell viability. Thus, it is of therapeutic interest to understand the molecular mechanism behind the overexpression of Rac1b through alternative splicing. Here we describe that ASF/SF2 and SRp20 are two antagonistic splicing factors regulating Rac1b expression in colorectal tumor cells. Using an Rac1 minigene, we identified that SRp20 increased skipping of alternative exon 3b in HT29 colorectal cells, whereas ASF/SF2 increased its inclusion. The depletion of the endogenous expression of these splicing factors by specific small interfering RNA confirmed that ASF/SF2 acts as an enhancer of endogenous Rac1b splicing, whereas SRp20 acts as a silencer. Point mutations in exon 3b defined two adjacent regulatory regions required for skipping or inclusion of exon 3b, which are recognized in vitro by SRp20 and ASF/ SF2, respectively. Both splicing factors were found to be regulated by upstream signaling pathways: the inhibition of the phosphatidylinositol 3-kinase pathway increased protein levels of ASF/SF2 and promoted Rac1b, whereas activation of b-catenin/TCF4 increased expression of SRp20 and inhibited that of Rac1b. Together, these data reveal that signaling pathways act in concert to target independent splicing factors and achieve the correct combinatorial code to regulate alternative splicing of the small GTPase Rac1.
INTRODUCTION
The expression of human genes involves their transcription into a pre-messenger RNA that is further processed to splice out introns and join exon sequences. It is now well documented that the majority of human genes can produce more than one mature messenger RNA (mRNA) through alternative patterns of intron removal or exon skipping (1) (2) (3) . This allows the synthesis of multiple mRNAs from a single gene, and these transcripts can differ in mRNA stability and translation or encode protein variants with altered functional properties. In particular, alternative spliced exons frequently code for unstructured peptide regions and thus may modify the function or the regulation of a protein without affecting its structural integrity (4) . Hence, the process of alternative splicing increases the functional complexity of gene expression from a genome. At present, no simple structure/function prediction exists to provide evidence of biological relevance for a given alternative spliced variant, but many examples have been described of individual variants with novel protein properties (e.g. reviewed in [5] [6] [7] .
One striking example is alternative splicing of the small GTPase Rac1, a member of the Rho family controlling signaling pathways that regulate the actin cytoskeleton and gene transcription (8, 9) . When in the active GTP-bound conformation, Rac1 interacts with downstream effector proteins and activates signaling cascades. In tumors, Rac1 activation is known to become deregulated (10) , and one recently unraveled mechanism is through increased expression of alternative spliced Rac1b in colorectal or breast tumor samples (11, 12) . Rac1b differs in 57 nucleotides resulting from the in-frame inclusion of alternative exon 3b (13) . The resulting Rac1b protein adopts predominantly the active GTP-bound conformation in cells. This reflects altered regulatory properties because of an increased intrinsic nucleotide exchange activity, a decreased rate of GTP hydrolysis and a failure to interact with Rho-GDI, a major downregulating factor in vivo (12, (14) (15) (16) (17) . Furthermore, the variant Rac1b displays unique signaling properties. It does not stimulate several classical Rac signaling pathways, including lamellipodia formation or the activation of protein kinases PAK1 or JNK. However, Rac1b retains the ability to stimulate the NF-kB pathway (18, 19) , which initiates an anti-apoptotic transcriptional response and also promotes cell cycle progression by an increase in cyclin D1 expression (20 -23) .
These different functional properties are apparently selected for in some tumor cell types. For example, Rac1b promoted epithelial -mesenchymal transition of mouse mammary epithelial cells (17) and contributed to further activate Wnt signaling in HCT116 colorectal cells (24) . In addition, some colon tumors that carry the oncogenic B-Raf V600E mutation depend on increased Rac1b expression to sustain tumor cell survival (25, 26) . However, the molecular details of how changes in alternative splicing lead to Rac1b overexpression remain unclear.
Alternative splicing events can be modulated by changes in the protein levels of individual splicing factors. For example, the relative concentrations of SR proteins and hnRNP factors expressed in a given cell will affect splice site choices in those pre-mRNAs containing respective regulatory elements (27 -29) . Altered expression of splicing factors was also described in various tumor types (30 -32) . In addition, splicing factors can be regulated through post-translational modification in response to cellular signaling pathways (reviewed in 33 -35) . For example, activation of the p38-MAP kinase pathway led to phosphorylation of hnRNP A1, resulting in its cytoplasmic sequestration and altered splicing of an adenovirus reporter gene (36) . Also, phosphorylation of SRp40 by AKT2 has been shown to regulate alternative splicing of protein kinase C bII (37, 38) , and the phosphatidylinositol 3 (PI3)-kinase pathway mediates alternative splicing of fibronectin in response to growth factor stimulation (39) .
These examples provide a mechanistic framework for how alternative spliced variants can be generated in response to signaling pathways; however, our limited understanding about these events derives from a careful analysis of candidate gene examples. In this manuscript, we present a further concept for the signaling -splicing connection in which the combination of two oncogenic signaling pathways acts on antagonistic SR proteins. We dissected the molecular regulation of Rac1 alternative splicing in colorectal cancer cells and found that ASF/SF2 and SRp20 exhibit antagonistic effects on alternative spliced exon 3b, in the context of both a minigene and the endogenous transcript. The data lead us to propose a model for the genetic tumor context in which overexpression of Rac1b can be selected for to promote colon tumorigenesis.
RESULTS

An Rac1 minigene approach identifies candidate regulatory splicing factors
Previously, we reported that the mammalian RAC1 gene contains seven coding exons (Fig. 1A) , which give rise to two alternative transcripts, Rac1 and Rac1b (11, 13) . Typically, exon 3b is skipped, and Rac1 is the predominant transcript produced. However, exon 3b-containing variant Rac1b has been found overexpressed in a subset of colorectal tumors and this promoted tumor cell survival (26) . In order to study the molecular regulation of this splicing event in tumor cells, we first selected colorectal cell lines with different levels of Rac1 and Rac1b expression. As shown in Figure 1B , SW480 cells express only Rac1 transcript and protein, whereas DLD-1 and HT29 cells express Rac1 as well as different levels of the alternative Rac1b transcript and protein. In these cell lines, we also compared the activated GTP-loaded Rac1 and Rac1b protein pools using a PAK-CRIB domain pull-down assay. In HT29 cells, a predominant activation of Rac1b over Rac1 was observed, although quantification of Rac1b transcripts by real-time PCR indicated that only 10% of the Rac1 pre-mRNA was spliced into Rac1b transcripts (not shown). Thus, the structural differences resulting from exon 3b inclusion lead to hyperactivation of Rac1b, and this is in agreement with previously published data (14 -17) . These results demonstrate that small changes in alternative Rac1 splicing are sufficient to generate Rac1b protein levels that have a profound effect on the activated, GTP-loaded Rac1 pool in colorectal cells.
In order to determine how the alternative splicing event of the RAC1 pre-mRNA is controlled, we first checked for the presence of genomic mutations in the three cell lines. A genomic RAC1 fragment ranging from 286 bp upstream to 224 bp downstream of exon 3b was amplified and sequenced. The three fragments were wild-type without any mutation that could account for the observed splicing differences. To study A CRIB-domain pull-down assay followed by western blot (bottom) demonstrates the amount of active GTP-bound Rac1 and Rac1b in the indicated cell lines. Note that Rac1b protein is expressed in low amounts compared with Rac1 but adopts predominantly the active GTP-bound conformation.
how this splicing event is regulated, we constructed a minigene and cloned the genomic region between exon 3 and exon 4 of the RAC1 gene into a pcDNA3 vector backbone ( Fig. 2A) . The minigene was transfected into SW480 and HT29 cells, and the minigene-derived transcripts were found to recapitulate the endogenous Rac1 and Rac1b expression patterns of these cell lines ( Fig. 2A) . With this RAC1 minigene tool, we analyzed the effect of a panel of known splicing factors on exon 3b inclusion. HT29 cells were co-transfected with the minigene, and the indicated factors and transcript ratios were quantified by real-time PCR (Fig. 2B) . We found that overexpression of two splicing factors had the most significant effect: SRp20 led to strong exon 3b skipping, whereas ASF/SF2 promoted inclusion of exon 3b by over 2-fold. We then asked whether SRp20 and ASF/SF2 affected the RAC1 exon 3b specifically and found that both factors exhibited different effects on alternative skipped exons in the PTB-derived minigene pG11 (40) or the FAS minigene (41) (Supplementary Material, Fig. S1 ). We concluded that ASF/SF2 and SRp20 were two candidate splicing factors regulating alternative splicing of Rac1 exon 3b.
Depletion of ASF/SF2 or SRp20 affects endogenous Rac1/ Rac1b splicing ratios
In order to test the relevance of the observed splicing effects for endogenous Rac1b levels, we first established the experimental conditions to deplete expression of ASF/SF2 and SRp20 using small interfering RNA (siRNA) oligonucleotides. Transfection of the siRNAs indicated in Figure 3A into HT29 cells led to efficient depletion by .80% for each factor. In these tests, the depletion of SRp55 served as a negative control and that of 9G8 was included, because it shares some binding motifs with SRp20 (42, 43) . Under the described experimental conditions, the relative changes in endogenous Rac1b expression were quantified by real-time PCR in HT29 cells following the depletion of each of the four splicing factors (Fig. 3B) . The depletion of ASF/SF2 strongly inhibited endogenous Rac1b generation. In contrast, the suppression of SRp20 and 9G8 increased endogenous Rac1b compared with cells transfected with control or SRp55-specific siRNAs. The opposite effects were observed when these four splicing factors were overexpressed in HT29 cells, although transfection was less than with siRNAs. In particular, overexpression of ASF/SF2 promoted, whereas SRp20 and 9G8 inhibited, the generation of endogenous Rac1b compared with control or SRp55-transfected cells. These data confirm the results obtained in the minigene approach and substantiate the identification of ASF/SF2 and SRp20 as candidate regulators of Rac1 alternative splicing.
We next asked whether the relative expression of ASF/SF2 and SRp20 in the colorectal cell lines would correlate with the level of endogenous Rac1b. When compared with SW480 cells, which do not express endogenous Rac1b, we found that HT29 cells clearly expressed more ASF/SF2 and less SRp20, both at transcript and protein levels by RT-PCR or western blot, respectively (Fig. 3C) . We therefore reasoned that the experimental manipulation of ASF/SF2 and SRp20 levels in SW480 cells should provoke increased expression of Rac1b. We observed that overexpression of ASF/SF2 in SW480 cells led to some increase in Rac1b and this could further be raised upon simultaneous depletion of SRp20, now reaching Rac1b levels normally detected in DLD-1 cells (Fig. 3D) . These results provide a proof of principle that ASF/SF2 acts as an enhancer for exon 3b inclusion, whereas SRp20 is a silencer promoting exon 3b skipping. The Rac1 exon 3b sequence contains binding sites for ASF/SF2 and SRp20
The observed effects of ASF/SF2 and SRp20 on alternative splicing of Rac1b suggested that these factors could bind directly to exon 3b in the Rac1 pre-mRNA. For the identification of such binding sites, we first aligned exon 3b sequences from various species and identified conserved nucleotide positions (Fig. 4A) . A series of conserved or control nucleotides were then mutated in the RAC1 minigene (Fig. 4B) , and the resulting constructs transfected into HT29 cells (Fig. 4C ). Mutant minigene-derived transcripts were amplified by RT -PCR and the ratios of exon 3b-containing transcripts quantified. This systematic analysis identified that nucleotide changes at exon positions þ7 and þ11 strongly inhibited exon 3b inclusion (exonic mutants E1.0 and E1.2), whereas changes at positions þ18 and þ19 promoted constitutive inclusion of exon 3b (mutants E2.0 and E2.1) (Fig. 4C) . Together, these data indicated that exon 3b contains an exonic splice enhancer element followed by a silencer element. From the experiments described earlier, we postulated that these elements would be recognized by ASF/SF2 and SRp20, respectively.
We further evaluated the exon 3b sequence and its mutants using bioinformatic software to recognize exonic splicing regulatory elements. The ESEfinder program (44; available at http:// rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) as well as the Splicing Rainbow software (45; available at http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8) predicted that mutants E1.0 and E1.2 would interrupt an ASF/SF2-binding site, and the Fairbrother and Wang algorithm at the ESR search (46; available at http://ast.bioinfo.tau.ac.il/ESR.htm) and SRp20 levels can force SW480 cells to include exon 3b. The western blot (lower panel) documents the ASF/SF2 and SRp20 levels under the three different experimental conditions (control vector, or T7-tagged ASF/SF2, or T7-tagged ASF/SF2 combined with siSRp20 oligos), whereas the black bars in the graph represent the corresponding minigenederived transcript analyses (top panel). Note the progressive increase in exon 3b-containing transcripts upon overexpression of enhancer ASF/SF2 and the depletion of silencer SR20, approximating splicing ratios to that normally observed in untransfected DLD-1 cells (gray bars).
predicted generically the loss of an exonic splice enhancer. With regard to positions þ18 and þ19 of exon 3b, the algorithms from the C. Burge Laboratory (Fairbrother and Wang (46) as well as the FAS-ESS (47); available at http:// genes.mit.edu/fas-ess/) identified a putative exonic splice silencer at this position, which became interrupted by mutants E2.0 and E2.1. A similar mutational approach was applied to conserved nucleotides near the 5 0 end of the downstream intron 3b; however, no significant changes in exon 3b inclusion were observed (data not shown). For direct experimental demonstration that ASF/SF2 binds the predicted motif around nucleotides þ7 and þ11, the wildtype exon 3b sequence as well as mutant E1.0 and E2.0 sequences were in vitro-transcribed and radiolabeled, then incubated in the presence of recombinant ASF/SF2 and analyzed in electrophoretic mobility shift assays (EMSA). We found that increasing amounts of recombinant ASF/SF2 led to a clear shift in electrophoretic mobility of the wild-type and the E2.0 probe, and this shift was abolished by excess unlabelled probe (Fig. 4D) . In contrast, mutant probe E1.0 revealed a strongly reduced affinity for ASF/SF2, confirming the bioinformatic predictions.
Because in eukaryotic cells splicing factors can be posttranslationally modified and differ from recombinant protein in binding affinity or subcellular localization, we wished to confirm the EMSA data with nuclear extracts. ASF/SF2 and SRp20 were overexpressed in DLD-1 cells, and nuclear proteins extracted and incubated with the radiolabeled exon 3b and mutant probes. Confirming the result with recombinant protein, we observed that the presence of increasing ASF/ SF2-containing nuclear extracts caused a mobility shift of wild-type exon 3b and mutant E2.0 probes (Fig. 5A ). The shifted complex was diminished by adding an excess unlabelled probe and was super-shifted in the presence of an ASF/SF2 antibody, but not a control antibody. As observed before, mutant E1.0 with a disrupted ASF/SF2 recognition motif was hardly recognized by nuclear extracts and no clear super-shift was observed (Fig. 5A) . When the same set of experiments was repeated with nuclear extracts expressing SRp20, we obtained a comparable mobility shift of wild-type exon 3b, but now mutant probe E1.0 exhibited the shift, whereas probe E2.0 was inefficiently recognized (Fig. 5B) . The exon 3b and mutant probes were also incubated with a recombinant N-terminal SRp20 fragment; however, this fragment apparently did not bind to RNA (not shown).
The EMSA data revealed that point mutations E1.0 and E2.0 significantly decreased the binding affinities for Figure 5 . EMSA with nuclear extracts from colorectal cells. (A) Nuclear extracts were prepared from DLD-1 cells transfected with ASF/SF2, then 0.5 or 1 mg incubated with the indicated probes and complexes separated in non-denaturing acrylamide gels. To verify the specificity of the observed complexes, additional aliquots were incubated with an excess of unlabeled probe, or with an anti-ASF/SF2 antibody or a control antibody. Note the super-shifted bands (arrow heads) in the presence of anti-ASF/SF2, and also that mutant probe E1.0 has a strongly reduced affinity to ASF/SF2. (B) As described for (A) except that nuclear extracts were prepared from DLD-1 cells transfected with SRp20. Note the super-shifted bands (arrow heads) in the presence of anti-SRp20, and that mutant probe E2.0 has a strongly reduced affinity to SRp20. (C) Restoration of normal splicing patterns from mutants E1.0 and E2.0. The significantly reduced binding affinities of ASF/SF2 to mutant probe E1.0 as well as of SRp20 to probe E2.0 were compensated by co-expressing the respective mutant minigenes with the corresponding ASF/ SF2 or SRp20 constructs into HT29 cells. The western blot (lower panel) shows increasing expression levels of ASF/SF2 or SRp20 levels. Under these conditions, minigene-derived transcripts were amplified by RT-PCR and stained following gel electrophoresis (middle). Relative band intensities were determined by densitometric analysis and displayed on a logarithmic scale for proportional visualization of positive and negative changes (top graph). Note that overexpression of these factors restored exon 3b inclusion almost to wild-type levels.
ASF/SF2 or SRp20, respectively, but did not fully ablate protein binding. We therefore assumed that overexpression of ASF/SF2 should be able to compensate the reduction in affinity towards the exon 3b mutant E1.0, and overexpression of SRp20 should compensate mutant E2.0. We tested this by co-transfecting the mutant minigenes E1.0 and E2.0 with increasing amounts of either ASF/SF2 or SRp20 and analyzed the minigene-derived transcripts. As shown in Figure 5C , increasing amounts of ASF/SF2 partially restored exon 3b inclusion from mutant E1.0, and overexpression of SRp20 restored skipping of exon 3b from mutant E2.0 to near-wild-type minigene levels.
We further excluded that the minigene mutants created binding sites for the respective antagonistic splicing factor. In particular, skipping of exon 3b due to minigene mutation E1.0 could be caused by increased binding of SRp20; however, the knock down of SRp20 in HT29 cells did not abrogate exon 3b skipping from this mutant. Conversely, the preferential inclusion of exon 3b in mutant E2.0 could reflect an increased affinity for ASF/SF2 rather than impaired SRp20 binding; however, siRNA-mediated downregulation of ASF/SF2 expression only partially decreased the inclusion of exon 3b from this mutant (Supplementary Material, Fig. S2 ).
Together, these data suggest that alternative spliced exon 3b contains neighboring positive and negative splicing regulatory elements that are recognized by splicing factor complexes containing either ASF/SF2 or SRp20, respectively.
PI3-kinase and b-catenin signaling pathways affect Rac1b expression
Our data so far identified ASF/SF2 and SRp20 as key splicing factors regulating Rac1b expression in colorectal cells. Because Rac1b is overexpressed in a group of colorectal tumors, we asked which upstream oncogenic signaling pathways would act on these SR proteins and trigger the Rac1 exon 3b splicing event.
One hallmark oncogenic pathway activated in many colorectal tumors is Wnt signaling, which recruits cytosolic b-catenin as a transcriptional co-activator (48) . Very recently, we found that the SFSR3 gene encoding SRp20 is a transcriptional target for activated b-catenin/TCF4 complexes, leading to increased SRp20 protein levels (49) . We therefore tested in colorectal cells the expression of Rac1b following either pathway stimulation with an activated b-catenin mutant or pathway inhibition with a dominant negative TCF4 mutant. Endogenous Rac1b levels were found to clearly respond to b-catenin/TCF4-induced changes in SRp20 protein levels. In particular, we observed that the inhibition of Wnt signaling decreased SRp20 and increased Rac1b levels (Fig. 6A) . This is in agreement with the data in Figures 3B and 5B that revealed SRp20 as a silencer of exon 3b inclusion. This finding suggested that tumors with low Wnt pathway activation are permissive to overexpression of Rac1b.
Furthermore, we suspected the existence of signals that can directly promote Rac1b overexpression via ASF/SF2. We tested the effect of three MAP kinase and the PI3-kinase pathways. The inhibition of ERK, JNK or p38 MAP kinase activities by the respective specific inhibitors U0126, SP600125 or SB203580 had no significant effect on endogenous Rac1b levels within 24 h ( Fig. 6B; data not shown) . Similarly, no effect was observed following transfection of kinase-dead JNK or p38 mutants ( Fig. 6B ; data not shown). In contrast, interfering with the PI3-kinase signaling by cell treatment with 10 mM inhibitor LY294002 revealed a 1.5-fold increase in Rac1b within 24 h. Similarly, overexpression of the counteracting phosphatase PTEN or of a kinase-dead mutant of the downstream effector kinase AKT significantly induced Rac1b expression within 24 h. Under the same experimental conditions, we found that PI3-kinase inhibition (by LY294002 treatment or following overexpression of PTEN) led to increased expression of endogenous ASF/SF2, at both the transcript and the protein levels (Fig. 6B) . In control experiments, these conditions of PI3-kinase inhibition did not affect endogenous expression of another splicing factor, hnRNP A1 (data not shown). We observed no change in ASF/SF2 expression when the p38 MAP kinase activity was inhibited (Fig. 6B) .
Together, these data provide evidence that the PI3-kinase and b-catenin signaling pathways affect the expression of ASF/SF2 and SRp20, respectively, and consequently modify the generation of Rac1b.
DISCUSSION
A major contribution of the present work is the demonstration that different cellular signaling pathways act in concert to regulate a specific alternative splicing event. By synchronizing the expression of two SR proteins with antagonistic roles, the pathways regulate inclusion or skipping of an alternative exon. The example studied is alternative splicing of exon 3b of the signaling small GTPase Rac1.
Experimental data from cell lines and normal tissues have revealed that exon 3b is usually either skipped or included into only a small transcript fraction (11, 17) . It has typical features of alternative exons such as its small size of 57 bp and a poorly conserved polypyrimidine tract. The polypyrimidine tract is an important splicing regulatory element at the splice acceptor site, and its length usually correlates with the efficiency of exon inclusion. Calculating the consensus values (CVs) that reflect the 'strength' of a polypyrimidine signal (50; online tool at http://ast.bioinfo.tau.ac.il/SpliceSiteFrame. htm), a weak tract becomes evident for exon 3b (CV ¼ 75.08) when compared with the CVs of the surrounding exons 3 (83.41) and 4 (92.25) . In agreement, we observed that single-point mutations, which strengthen the exon 3b polypyrimidine tract in the RAC1 minigene, were sufficient to promote nearly constitutive inclusion of exon 3b (data not shown). These data and the absence of genomic mutations in the analyzed cell lines suggested that differences in Rac1b expression are based on a regulated alternative splicing event.
In this work, we demonstrate that Rac1 alternative splicing is regulated by the SR proteins ASF/SF2 and SRp20 in colorectal cells. In order to dissect the mechanisms regulating the alternative Rac1b splicing event, we first constructed an RAC1 minigene that recapitulates the endogenous splicing decisions in colon cell lines. We then tested a panel of candidate splicing factors for their effect on the minigene and were fortunate to identify one Rac1b promoting and another silen-cing factor. Their physiological roles in Rac1 alternative splicing in colorectal tumor cells were then confirmed at the endogenous level by RNA interference experiments. Moreover, these factors recognized probes transcribed in vitro from exon 3b. Altogether, our data lead us to propose that exon 3b contains an exonic splice enhancer recognized by ASF/SF2 adjacent to an exonic silencer bound by SRp20. In our experimental system of colorectal cell lines, we observed that the relative protein concentrations of ASF/SF2 versus SRp20 determined the alternative splicing rate. Not only did the endogenous protein levels of both factors correlate with the amount of Rac1b expressed in different cell lines, but also the experimental manipulation of ASF/SF2 and SRp20 expression levels by RNAi or splicing factor overexpression changed alternative splicing of exon 3b.
As upstream events regulating the relative protein concentrations of ASF/SF2 versus SRp20, we identified two signaling pathways that affected their expression and promoted a corresponding increase or decrease in Rac1b. The Wnt pathway activates the b-catenin/TCF4 transcriptional complex, for which the SFSR3 gene encoding SRp20 is a direct target (49) . Pathway stimulation increased SRp20 levels that we found to act as a silencer on exon 3b, leading to decreased Rac1b generation. The PI3-kinase pathway was found involved in regulating the antagonistic factor ASF/SF2. The inhibition of this pathway increased expression of both the transcript and protein levels of ASF/SF2, which acts as an enhancer of exon 3b inclusion. Consequently, an increased Rac1b expression was observed. Together, this shows that different signaling pathways concurrently target independent splicing factors in order to exert control over alternative splicing of Rac1b.
Numerous studies have documented that the relative abundance of antagonistic splicing factors, including ASF/SF2 and SRp20, can affect splicing decisions (e.g. [51] [52] [53] . It is therefore well accepted that splicing factor expression levels are a major mechanism to trigger differences in alternative splicing patterns. According to current knowledge, antagonistic splicing factors regulate alternative splicing through a combinatorial mode of action with a subset of individual genes responding to a given factor combination or activation (28, 29) . The novelty of our findings resides in the demonstration that a concerted signaling level of apparently independent pathways is essential to promote a specific alternative splicing event. This adds further complexity to the regulation -DN) , or a non-degradable GFP-b-catenin mutant (bCat-CA). The expression of Rac1b was quantified by real-time PCR (top panel). The western blots below the graph show the indicated expression levels of the transfected GFP-tagged constructs, the resulting changes in endogenous SRp20 protein levels and, as controls, the levels of ASF/SF2 and a-tubulin. Note that pathway activation by transfection of bCat-CA promoted an increase in SRp20 but a decrease in Rac1b expression. (B) Effect of PI3-kinase and p38 MAP kinase pathway inhibition on alternative splicing of Rac1b. HT29 cells were treated with inhibitors LY294002 (10 mM) or SB203580 (1 mM), or transfected with constructs encoding control vector, or PTEN, or kinase-dead mutants of either AKT or p38. RNA was extracted after 24 h, endogenous Rac1b quantified by real-time PCR and data graphically displayed. (C) Effect of PI3-kinase and p38 MAP kinase pathway inhibition on ASF/SF2 expression levels. Cells were treated as described earlier and whole-cell lysates analyzed for changes in ASF/SF2 transcript (by real-time PCR; top) and protein levels (by western blot, using tubulin levels as loading control; bottom). Note that, in the presence of the PI3 inhibitor or upon overexpression of PTEN, an increase in ASF/SF2 was observed that correlated with increased Rac1b expression.
of alternative splicing and implies that certain splice site choices require a balanced stimulation of multiple pathways.
It is possible that Rac1b alternative splicing is further modulated through protein phosphorylation of ASF/SF2 or SRp20. For example, our observation is suggestive that overexpression of PTEN promoted an increase in ASF/SF2 expression, whereas that of a kinase-dead AKT mutant did not. However, the kinase-dead AKT mutant still induced some increase in Rac1b, although less pronounced than following PTEN expression. This suggests that post-translational modification of ASF/SF2 also contributes to the regulation of exon 3b inclusion. Indeed, nuclear and cytoplasmic functions for ASF/SF2 are known to be modulated by phosphorylation (54, 55) and AKT has been recently described to phosphorylate ASF/SF2 in vitro (56) . The inhibition of PI3-kinase pathway has previously been implicated in the regulation of other alternative splicing events such as of the fibronectin and PKC bII genes (39, 57, 58) , but mechanistic details remained uncharacterized. Further experiments will be required to clarify whether and how the PI3-kinase pathway affects ASF/SF2 expression at the transcriptional or the posttranscriptional level, and what role of phosphorylation by one of the AKT kinases is playing. It is possible that the PI3-kinase pathway regulates other SR protein regulators besides AKT, such as the SRPK and Clk/Sty family of protein kinases. These operate in the cytosol (59) and may antagonize the effect of AKT on SR proteins (56) .
Our observation that PI3-kinase signaling inhibited expression of Rac1b (Fig. 6B) helps to clarify genetic pathways leading to colorectal tumorigenesis. One group of tumors show oncogenic KRAS mutations and these increase cell proliferation via ERK signaling and provide pro-survival stimuli via the PI3 kinase/Rac1 pathway (60) . This group is represented by SW480 cells, which do not express endogenous Rac1b (Fig. 3C) , and this is compatible with mutant K-Ras strongly activating PI3-kinase, thus leading to decreased ASF/SF2 expression. Similarly, HCT116 colorectal cells carry an H1047R mutation in the PIK3CA gene and do not express Rac1b.
In contrast, HT29 cells have wild-type KRAS and PIK3CA genes but carry the alternative oncogenic BRAF mutation (26) . B-Raf operates downstream of K-Ras in the ERK pathway and thus cannot stimulate PI3-kinase directly. In agreement, HT29 cells express more ASF/SF2 and more Rac1b. HT29 cells represent another group of colorectal tumors in which the oncogenic B-Raf V600E mutation occurs associated with overexpressed Rac1b (26) . Whereas B-Raf V600E primarily stimulates cell proliferation, Rac1b signaling sustains tumor cell survival (26) . However, the molecular details of how Rac1b becomes overexpressed remained unclear. The data presented in this manuscript now allow us to propose a mechanism for Rac1b overexpression: genetic lesions that initiate colorectal tumorigenesis without enhancing PI3-kinase and b-catenin signaling promote the selection of cellular backgrounds with increased ASF/SF2 levels relative to SRp20. These cellular settings would favor Rac1b overexpression, leading to increased tumor cell survival and subsequent tumor progression.
In conclusion, cellular signals are known to influence the outcome of alternative splicing, but most knowledge in this field has provided evidence for a 'one signaling pathway, one gene'-type of regulation. In this article, we revealed that different signaling pathways need to act in concert so that the targeting of independent splicing factors can provide the correct combinatorial code to regulate alternative splicing of the small GTPase Rac1. 
MATERIALS AND METHODS
Cell
DNA constructs
The following previously published constructs were used: HA-tagged TATA-binding protein (TBP) (11); HA-tagged U2AF65 (61) , and U2AF35 (62); Myc-tagged hnRNPA1 (63); T7-tagged constructs of SC35, SRp55, SRp40, SRp30, SRp20, ASF/SF2 and 9G8 (64); dominant negative TCF-4 (TCF-DN) and constitutively active b-catenin (b-Cat-CA) (49); pCMV-PTEN (65); kinase-dead AKT mutant HA-PKB-K179A (66; recloned as a BglIII/EcoRI fragment into pEGFP); kinasedead Flag-p38 mutant K53M (67); Myc-JNK (68; recloned as BamHI/XbaI fragment from pRev-TRE SAPKbeta/MKK7 following site-directed mutagenesis into kinase-dead mutant K56R/K57R); splicing reporter minigenes PTB-pG11 (40) and FAS (41) . All constructs were confirmed by automated DNA sequencing.
For the RAC1 minigene construct, a previously described 4.3 kb fragment containing intron 3 and the adjacent ends of exons 3 and 3b (13) was first subcloned into pCR-XL-TOPO (Invitrogen). Exon 3 was then complemented by exchanging a BamHI/BsmI fragment amplified from BAC clone RP11-425P05 with primers RACBAMEX3-F (5 0 -GGA TCC TTT GAC AAT TAT ACT TCT GCC AAT G) and RACINT3-BSMR (5 0 -CAG ACA CTG GTA TCT GAG CAT CTG T). Intron 3b and exon 4 were added to this construct as an NsiI fragment amplified from BAC clone RP11-425P05 with primers Not-Int3-F (5 0 -GCG GCC GCC GAT AAG AGG TTA TAT TGA) and RACEX4NOT-R (5 0 -GCG GCC GCT TTG CAC GGA CAT TTT CAA ATG). The assembled genomic region between exon 3 and exon 4 of the human RAC1 gene was then cloned as a BamHI/NotI fragment into a pcDNA3-HA vector to generate the RAC1 minigene. Conserved nucleotides in exon 3b of RAC1 minigene were mutated using the QuickChange site-directed mutagenesis kit (Stratagene) following the manufacturer's instructions.
Nucleic acid amplifications, semi-quantitative and real-time RT -PCR
Genomic DNA was extracted from SW480, DLD-1 and HT29 cells using the Wizard DNA Extraction Kit (Promega), and an RAC1 gene fragment encompassing 286 bp upstream and 224 bp downstream of exon 3b was amplified with primers Int3KSP-F1 (5 0 -GCG GCC GCT TAC CCA CCG GCT TGA ATT A) and RacInt3b-R2 (5 0 -GCT GCC TGT CAC AGC TCC CA).
Total RNA was extracted from cell lysates with the RNAeasy kit (Qiagen) and 1 mg reverse-transcribed using random primers (Invitrogen) and Ready-to-Go You-Prime Beads (GE Healthcare, Buckinghamshire, UK). 0 -GAG CGG GAA TTT GAG CGG ATG C) and Pol II-R (5 0 -GAA GGC GTG GGT TGA TGT GGA AGA). Amplification reactions were performed using AmpliTaq polymerase (Perkin-Elmer, Wellesley, MA, USA) at 608C for 30 cycles for endogenous Rac1/Rac1b, minigene (RAC1, pG11 or FAS)-derived transcripts, 9G8, ASF/SF2 and SRp20, and at 668C for 28 cycles for Pol II. All reactions included an initial denaturation of 5 min at 948C and a final extension of 10 min at 728C, and each cycle contained 30 s of denaturation and extension. Semiquantitative analyses of transcript levels were established using serial dilutions of control cDNAs in order to determine the linear amplification phase for each PCR reaction. Products were separated on 2% agarose gels stained with ethidium bromide, images recorded digitally and band intensity quantified using ImageJ software followed by normalization to Pol II expression levels. Real-time PCR quantification was performed on an ABI Prism 7000 Sequence Detection System. Primers were designed using the ABI Primer Express software that amplified amplicons specific for endogenous Rac1b (78 bp) (5 0 -GGG CAA AGA CAA GCC GAT TG and 5 0 -CGG ACA TTT TCA AAT GAT GCA GG) or total Rac1 transcripts (i.e. Rac1þRac1b; 75 bp) (5 0 -CCT GCA TCA TTT GAA AAT GTC CG and 5 0 -CCC ACT AGG ATG ATG GGA GTG T) as well as for RAC1 minigene transcript ex3þ3bþ4 (5 0 -CAT GAT CGA CTA CGA CGT TCC TGA TTA TGC GG and 5 0 -ATA TCC TTA CCG TAC GTT TCT CCA A) or minigene transcript ex3þ4 (5 0 -CAT GAT CGA CTA CGA CGT TCC TGA TTA TGC GG and 5 0 -ACA AGC AAA TTG AGA ACA CAT CTG TT). Each cDNA sample was diluted 5-fold to guarantee accurate pipetting and 5 ml added to 300 nmol/l primers and SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). The cycling conditions comprised 10 min polymerase activation at 958C and 40 cycles at 958C for 15 s and 608C for 30 s. For standardization, all samples were analyzed against HT29 cDNA as a reference sample using the 7000 SDS 1.1 RQ Software (DDCT method; Applied Biosystems) (26) . Each sample was amplified in duplicate reactions and repeated in at least three independent experiments. No amplification was obtained when RNA was mock-reverse-transcribed without adding reverse transcriptase.
SDS -PAGE, western blotting and PAK CRIB-domain pull down assay
Samples were prepared and detected as described (19) . The antibodies used for western blots were custom rabbit polyclonal anti-Rac1b serum (14) ; mouse anti-Rac (clone 23A8) from Upstate Biotechnologies; rabbit anti-c-Myc (A-14) from Santa Cruz Biotechnology; mouse anti-SR proteins (clone 1H4), mouse anti-ASF/SF2 and mouse anti-SRp20 from Zymed-Invitrogen; rabbit anti-PTEN from Cell Signaling; mouse anti-Flag (M2), mouse anti-HA and mouse anti-a-tubulin (clone B-5-1-2, as loading control) from Sigma; rabbit anti-GFP (ab290) from Abcam; and T7-Tag antibody from Novagen/VWR. For densitometric analysis, films from at least three independent experiments were digitalized and analyzed using ImageJ software (NIH). The PAK-CRIB-domain pull down assay was as described (19) .
Electrophoretic mobility shift assays
Nuclear extracts for EMSA were prepared in 20 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol with protease inhibitors, as described (69) , diluted to adjust the salt concentration to the EMSA binding buffer and purified in Microcon spin columns (YM-10, Millipore) according to the manufacturer's instructions. Plasmid DNAs encoding the tested RNA probes were linearized at a BamHI site, transcribed in vitro in the presence of a[
32 P]CTP (400 Ci/mmol, 10 mCi/ml; Amersham Pharmacia Biotech) using a Maxiscript SP6 kit (Ambion), and purified with Microspin G-25 columns (GE Healthcare) according to the manufacturer's instructions. Either 0.5 or 1 mg of the indicated nuclear extracts or 50 -150 ng of recombinant ASF/SF2 (ProteinOne, Bethesda) or 100 -500 ng of SRp20 (N-terminal fragment 1-86 amino acid, Abnova) was incubated for 5 min at 308C in 20 ml reaction volumes containing EMSA binding buffer (12 mM HEPES, pH 7.9, 72.5 mM KCl, 3.2 mM MgCl 2 , 20 mM creatine phosphate, 20% glycerol, 1 mM DTT, 1 mM ATP, 40 U RNAsin, 125 ng of Escherichia coli tRNA and 0.5 mg BSA). Labeled RNA probes (8000 c.p.m., 5 -10 fmol) were denatured at 958C for 5 min, immediately chilled on ice and then added to the assay volume for 20 min at 308C followed by chilling on ice. Protein-RNA complexes were resolved in 8% non-denaturing polyacrylamide gels (acrylamide/bisacrylamide ratio of 29/1) in 0.5Â TBE buffer, which was then dried and autoradiographed.
